Actively Recruiting
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
Led by Huashan Hospital · Updated on 2022-05-24
2000
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how well and how safely Paxlovid works for treating patients hospitalized with COVID-19. This real-world study collects medical records from patients visiting Huashan Hospital affiliated to Fudan University between 2022 and 2027. The research aims to understand the effects of Paxlovid and factors that may influence the outcomes for COVID-19 patients. The study compares two groups: patients receiving Paxlovid therapy and those receiving routine therapy without Paxlovid. The exact use of Paxlovid is based on patients' medical history as recorded in their treatment. Data on demographics, clinical features, lab tests, treatment history, adverse reactions, and treatment results will be gathered and analyzed. Participants will have their viral shedding time and disease progression tracked for up to 28 days. Researchers will also monitor adverse events and recovery times. Data on how many patients test negative for the virus and their clinical recovery will be measured. The study collects information from medical records without altering patients’ usual care, and results will help understand Paxlovid's role in COVID-19 treatment.
CONDITIONS
Brief Title
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants who have a positive SARS-CoV-2 test result
- Participants who have one or more mild or moderate COVID-19 symptoms
- Participants aged 12 years or older
You will not qualify if you...
- No specific exclusion criteria in this real world study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 28 days
Participants receive Paxlovid therapy or routine therapy for COVID-19 as part of their medical care. Data on treatment and outcomes are collected.
Visits as part of routine hospital care during treatment period
Duration - Up to 28 days
Participants are monitored for safety and treatment outcomes including adverse events and recovery status after treatment.
Follow-up visits or data collection up to 28 days post-treatment
Trial Site Locations
Total: 1 location
1
Huashan Hospital Affiliated to Fudan University
Shanghai, China
Actively Recruiting
Research Team
F
Feng Sun, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here